Dow Obtains Patents for Production of Glycoproteins In Transgenic Plant Systems

04-Oct-2002 - SAN DIEGO, Oct. 1 - The Dow Chemical Company has acquired a global, exclusive assignment of patents involving significant technology in protein glycosylation for enabling the production of "mammalian- like" glycans in plants. Many protein-based therapeutics require glycosyl groups for full ...

Dendreon Corporation and Genentech to Collaborate on Trp-p8 Gene Platform

Potential Value of Deal Over $110 Million

15-Aug-2002 - Seattle, WA (August 13, 2002) – Dendreon Corporation today announced a collaboration with Genentech, Inc. for the research, development and commercialization of products derived from Dendreon’s Trp-p8 gene platform. The agreement concerns the development of monoclonal antibodies, small molecules ...

Abgenix And Diabetogen Sign Second Agreement To Develop Antibody Therapy Against Autoimmune Disease

16-Apr-2002 - Fremont, Calif. and London, Ontario, Canada - Abgenix, Inc., an antibody-based biopharmaceutical company, and Diabetogen Biosciences, Inc., a privately-held biotechnology company, announced today the execution of a research collaboration, option and license agreement to discover and develop a ...

OGS and BioInvent form Therapeutic Antibodies Alliance

18-Mar-2002 - Oxford, UK and Lund, Sweden, 14 March 2002 - Oxford GlycoSciences Plc and BioInvent International AB announced today a three year collaboration to identify, develop, manufacture and commercialise novel therapeutic antibodies, which will target antigens provided by OGS and will be produced using ...

Key Milestones Achieved In Genentech's Biooncology Initiative

10-Dec-2001 - SOUTH SAN FRANCISCO -- Dec. 7, 2001 -- Genentech, Inc. today reported, in anticipation of upcoming major oncology meetings, key advancements in its portfolio of novel marketed and pipeline targeted therapies for the treatment of cancer, the number two fatal disease in the United States. ...

Abgenix Introduces Enhanced Version of XenoMouse Technology

05-Dec-2001 - FREMONT, Calif. Dec. 4, 2001--Abgenix, Inc. announced today at the IBC Antibody Engineering Conference in San Diego, Calif., the launch of new versions of XenoMouse® mice that produce fully human monoclonal antibodies that contain both lambda and kappa light chains. Other transgenic mouse ...